|
- IRMS - Nicolae Testemitanu SUMPh
- REVISTE MEDICALE NEINSTITUČšIONALE
- The Moldovan Medical Journal
- Curierul Medical 2009 - 2016
- Curierul Medical, 2014
- Curierul Medical, 2014, Vol. 57, Nr. 6
Please use this identifier to cite or link to this item:
http://hdl.handle.net/20.500.12710/7459
Title: | Sindromul hepatopulmonar |
Other Titles: | Hepatopulmonary syndrome |
Authors: | Tcaciuc, E. |
Keywords: | liver cirrhosis;portal hypertension;hepatopulmonary syndrome |
Issue Date: | 2014 |
Publisher: | The Scientific Medical Association of the Republic of Moldova |
Citation: | TCACIUC, E. Sindromul hepatopulmonar. In: Curierul Medical. 2014, vol. 57, no 6, pp. 58-66. ISSN 1875-0666. |
Abstract: | Background: Hepatopulmonary syndrome (HPS) is an important complication of liver cirrhosis. It is due to vasodilation and angiogenesis in the
pulmonary vascular bed, which lead to ventilation-perfusion mismatching, diffusion limitation to oxygen exchange, and arteriovenous shunting. Pulmonary
vasodilation in experimental HPS is mediated by a number of endogenous vasoactive molecules, including endothelin-1 (ET-1) and nitric oxide (NO).
Liver injury stimulates release of ET-1, which increases expression of ETB receptors in pulmonary endothelial cells. Activation of these receptors results in
the upregulation of endothelial NO synthesis (eNOS) and subsequent increased production of NO, which diffuses into vascular smooth muscle, causing
vasodilation. In addition, increased phagocytosis of bacterial endotoxin in the lung promotes activation of inducible NO synthase (iNOS), which also
contributes toward increased NO production. Bacterial translocation and subsequent monocyte accumulation may also stimulate pulmonary angiogenesis
in HPS, which may be partly controlled by genetic factors.
Conclusion: However, there remains a need for more human experimental data to support the development of new therapies targeting these proposed
mechanisms. Despite promising outcomes from treatment of HPS with several drugs, results can not be generalized to all patients due to the lack of
randomized trials. Promising drugs are considered Pentoxifylline, Methylene blue and Mycophenolate mofetil. Currently the most effective treatment
is liver transplantation. |
metadata.dc.relation.ispartof: | Curierul Medical |
URI: | http://repository.usmf.md/handle/20.500.12710/7459 http://moldmedjournal.md/wp-content/uploads/2016/09/Cm-6-2014-Electronic-version.pdf |
ISSN: | 1875-0666 |
Appears in Collections: | Curierul Medical, 2014, Vol. 57, Nr. 6
|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.
|